(Q46628463)

23 December 2017

title

Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects (English)

1 reference

23 December 2017

1 reference

Jules I Schwartz

1

1 reference

23 December 2017

Aimee L Dallob

2

1 reference

23 December 2017

Patrick J Larson

3

1 reference

23 December 2017

Omar F Laterza

4

1 reference

23 December 2017

Jutta Miller

5

1 reference

23 December 2017

Jane Royalty

6

1 reference

23 December 2017

Karen M Snyder

7

1 reference

23 December 2017

Derek L Chappell

8

1 reference

23 December 2017

Deborah A Hilliard

9

1 reference

23 December 2017

Mary E Flynn

10

1 reference

23 December 2017

Paul F Cavanaugh

11

1 reference

23 December 2017

John A Wagner

12

1 reference

23 December 2017

publication date

23 April 2008

1 reference

23 December 2017

The Journal of Clinical Pharmacology

published in

1 reference

23 December 2017

volume

48

1 reference

23 December 2017

issue

6

1 reference

23 December 2017

page(s)

745-754

1 reference

23 December 2017

GI risk and risk factors of NSAIDs

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Characterization of etoricoxib, a novel, selective COX-2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Nomenclature for COX-2 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Relationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Paired analysis of urinary thromboxane B2 metabolites in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Balancing prostanoid activity in the human vascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Double-label expression studies of prostacyclin synthase, thromboxane synthase and COX isoforms in normal aortic endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Celecoxib for the prevention of sporadic colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Role of prostacyclin in the cardiovascular response to thromboxane A2

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Possible mechanisms of drug-induced aspirin and clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008317590

21 January 2018

Identifiers

DOI

10.1177/0091270008317590

1 reference

23 December 2017

1 reference

23 December 2017